해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 안내 10.25. (금)

구분	보고서(영문)
제약/바이오/임상시험 (6건)	Venture Capital Investment Trends In Pharma - Q3 2024
	M&A Trends in Pharma - Q3 2024
	Results of Phase I Trial Shed Positive Light on UNI-494 for Acute Kidney Injury
	Q3 2024 CRO Activity and Intel Report
	Unresolved Clawback Issues Obstruct Greece’s Potential Pharmaceutical Framework Agreement
	Oral GLP-1 Receptor Agonist Rybelsus Reduces Risk of Cardiovascular Events in Type 2 Diabetes Patients
컨퍼런스/심포지엄/학회/기타 (12건)	EADV 2024: Atopic Dermatitis Observations
	AAO 2024: Rezolute’s RZ-402 Shows Promising Phase IIa Results in DME Patients
	AAO 2024: Nanoscope Therapeutics’ MCO-010 RESTOREs Vision in RP Patients
	AAO 2024: EyePoint’s EYP-1901 Proves Non-Inferiority to Aflibercept in DAVIO 2 Trial
	IDWeek 2024: Novel Antimicrobials Poised to Make a Difference
	AAO 2024: Brepocitinib Achieves Treatment Failure Reductions in NEPTUNE
	IDWeek 2024: Moderna’s Norovirus Vaccine mRNA-1403 Shows Potential in Phase I/II Trial
	AAO 2024: Neurodegeneration Marker Apolipoprotein E is Elevated in the Serum of Patients with Glaucoma
	AAO 2024: Phase II Study on the Safety of Intravitreal NT-501 Encapsulated Cell Therapy Implantation for Glaucoma Treatment
	AAO 2024: NMA Reveals that Vabysmo Achieves Superior CST Improvement Over Eylea HD
	IDWeek 2024: Highlights on the Detection and Prevention of NTM Outbreaks
	EADV 2024: Psoriasis and Hidradenitis Suppurativa Observations
질환별 (6건)	COPD Market Expected to Grow to $30.8 Billion in the 7MM by 2033
	Pertussis Transmission Reaches Pre-Pandemic Levels in US
	Opioid Addiction: Opportunity Assessment and Forecast
	Opioid Addiction Market to Reach $2.4 Billion Across 8MM by 2033
	Sepsis Deaths Are Still High, with 50% Mortality Within Two Years
	Bladder Cancer: Epidemiology Forecast to 2033